GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES

这项提议的目标是使用基因工程 开发安全有效的亚基的方法学 预防人类疟疾寄生虫感染的疫苗。 恶性疟原虫和间日疟原虫，人类最常见的形式 疟疾在世界范围内高度流行，并造成相当大的 发病率和死亡率。抗药性的增加是由 疟原虫强调了有效的免疫催产素的必要性。 对抗这种有机体。然而，目前还没有疟疾疫苗。 是存在的。我们计划调查这些病毒的免疫学特性 从基因上产生的各种寄生虫表面抗原 工程酵母。类似的表达系统目前正在被 用于生产其他疫苗(乙肝病毒 表面抗原)，以及用于治疗的酶和激素 在人类身上使用。纯化的重组蛋白将用于 啮齿动物和亚人灵长类动物的免疫原性研究 展望他们最终在人体上的临床试验。此外， 这些重组抗原的问世将有助于我们 对病机和基础的基本认识 免疫机制。

The objective of this proposal is to use genetic engineering methodologies for the development of safe and effective subunit vaccines for preventing infection by human malarial parasites. Plasmodium falciparum and P. vivax, the most common forms of human malaria, are highly prevalent worldwide and cause considerable morbidity and mortality. An increase in drug resistance by the Plasmodia has emphasized the need for an effective immunoprohylaxis against this organism. Currently however, no vaccine for malaria exists. We plan to investigate the immunological properties of various parasite surface antigens produced in genetically engineered yeast. Similar expression systems are currently being used for the production of other vaccines (Hepatitis B Virus surface antigens) and also for enzymes and hormones for therapeutic use in humans. Purified recombinant proteins will be used for immunogenicity studies in rodents and sub-human primates with a view to their eventual clinical trial in humans. In addition, the availability of these recombinant antigens will contribute to our understanding of basic aspects of pathogenesis and fundamental mechanisms of immunity.